title: Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
authors.affiliation: Vitreous, Retina, Macula Consultants of New York, and the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, New York, 10022, USA.
authors.forename: Ketan
authors.initials: K
authors.lastname: Laud
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
authors.forename: Jason
authors.initials: J
authors.lastname: Slakter
authors.forename: James M
authors.initials: JM
authors.lastname: Klancnik
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab